Abbott to Pay $700 Million for Off-Label Marketing of Depakote


Pleading guilty to marketing Depakote for behavioral problems in dementia patients, a purpose for which the drug was not approved, a federal judge has assessed Abbott pharmaceuticals a criminal fine of $500 million, forfeiture of $198.5 million, and a payment of $1.5 million to Virginia’s Medicaid Fraud Control Unit.

Article → 

Previous articleThe Structure of the Mindful Brain
Next articleCT Senator Submits Bill Limiting Antipsychotics in Nursing Homes
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected].